There is growing use of selective serotonin reuptake inhibitor antidepressant (SSRI) medications during the perinatal period to treat maternal affective disorders. Perinatal SSRI exposure can have a long-term impact on offspring neuroplasticity and behavioral development that remains to be fully elucidated. This mini-review will summarize what is known about the effects of perinatal SSRIs on plasticity in the developing hippocampus, taking into account the role that maternal stress and depression may have. Emerging clinical findings and research in animal models will be discussed. In addition, sexually differentiated effects will be highlighted, as recent work shows that male offspring are often more sensitive to the effects of maternal stress, whereas female offspring can be more sensitive to perinatal SSRIs. Potential mechanisms behind these changes and aims for future research will also be discussed. Understanding the impact of perinatal SSRIs on neuroplasticity will provide better insight into the long-term effects of such medications on the health and well-being of both mother and child and may improve therapeutic approaches for maternal mood disorders during the perinatal period.
Introduction
Up to 20% of women are diagnosed with depression or anxiety during the perinatal period [1] [2] [3] [4] . These affective disorders can have detrimental effects for both the mother and developing child, thus treatment is needed [4, 5] . Many antidepressant treatments are available to treat maternal affective disorders, with selective serotonin reuptake inhibitor medications (SSRIs) being the recommended first line of treatment [4, 6, 7] . SSRIs, with the exception of paroxetine, are considered safe for use during pregnancy as they have no major teratogenic effects on the fetus [8] . SSRI prescription rates for pregnant women in industrialized countries (including Canada, Iceland, Denmark, Sweden, UK, Italy, the Netherlands, and France) range between 2 and 7% and between 5 and 13% in Australia and the USA [6, 7, [9] [10] [11] [12] . These medications are expected to promote maternal mental health and thus promote the health and well-being of both the mother and child [13] . However, SSRIs can cross the placenta and, to a lesser degree, are found in breast milk, thereby modulating the serotonergic environment for the developing fetus and having potentially long-term effects on neurodevelopment [14] [15] [16] [17] .
Clinical research has shown that children exposed to SSRIs prenatally may be at increased risk of behavioral abnormalities including attentional deficits, neuropsychiatric disorders, and neurodevelopmental disorders [18] [19] [20] . As the hippocampus is a key mediator of behavior and cognition and receives substantial serotoninergic innervation, such effects are likely linked to SSRI-related changes in hippocampal development. Therefore, this mini-review will focus on how perinatal SSRIs affect plasticity in the developing hippocampus. First, we will briefly review how SSRIs during the perinatal period may alter the developing serotoninergic system, and then, we will review what is known about perinatal SSRI effects on biomarkers of neuroplasticity in clinical studies and measures of hippocampus plasticity from work in laboratory rodent models. Early-life exposure to maternal mental illness, in the presence of SSRIs, can also have a persistent effect on offspring neurobehavioral outcomes [21, 22] . Thus, the implications of both perinatal SSRIs and maternal stress-related disorders will be discussed in terms of offspring outcomes where possible [23, 24] . Understanding the long-term effect of perinatal SSRIs on hippocampus plasticity will aid in understanding the risks and benefits of exposure to these medications during the perinatal period.
Serotonin, SSRIs, and the developing hippocampus
During development, serotonin (5-hydroxytryptamine or 5-HT) plays an important role in regulating proliferation, migration, and differentiation of neurons as well as axonal connectivity and synaptic pruning [25] [26] [27] . A number of studies indicate that serotonin signaling during early life is critically involved in the development of neuronal circuits [27] [28] [29] [30] [31] [32] . Hence, any changes to serotonin levels and/or serotonergic system functioning during the perinatal period could disrupt the development of not only the serotonergic system in infants but also countless brain regions which receive serotonergic input, such as the hippocampus.
SSRIs act by blocking the serotonin transporter (SERT) on the presynaptic neuronal membrane and subsequently reducing serotonin reuptake, increasing serotonin's concentration in the synaptic cleft and aiding in chemical transmission between neurons which can have mood-stabilizing effects. As perinatal SSRIs target maternal SERT activity and are present in both the placenta and, at much lower levels, in breast milk [33] , the use of such medications during pregnancy and lactation suggests an effect on infant neural development. The consequences of perinatal SSRI exposure may not occur immediately after birth but may manifest later during childhood, adolescence, or even in adulthood [14, 34, 35] .
Perinatal SSRI treatment can increase hippocampal serotonin levels in adolescent and adult male mice [36] and preadolescent male and female offspring [37] . Interestingly, earlylife exposure to SSRIs also normalizes hippocampal levels of serotonin and serotonin's metabolite 5-hydroxyindolacetic acid (5-HIAA) in prenatally restraint stressed offspring at weaning [38] , serotonergic transmission in the ventral hippocampus of adolescent rat offspring after prenatal dexamethasone treatment [39] , and serotonin turnover (via 5-HIAA/5-HT ratios) in the hippocampus of prenatally stressed male mouse offspring (Table 1) [36]. Although not well studied in the hippocampus, perinatal SSRIs do affect serotonergic receptors in cortical and hypothalamic brain regions, and thus, many layers of the serotonergic system are likely altered by perinatal SSRIs [49] [50] [51] . It should not be forgotten that maternal stress can also have enduring effects on serotonin, even when combined with perinatal SSRIs. Recently, we have shown that pregestational chronic unpredictable stress results in significantly reduced hippocampal serotonin levels in preadolescent offspring, particularly in female offspring, regardless of perinatal fluoxetine exposure [17, 34] . Others have shown that pregestational stress increases serotonin levels and decreases serotonin transporter expression in the hippocampus of fetal rats [52] and that prenatal stress increases serotonin in weanling offspring, regardless of fluoxetine exposure. Changes in early-life serotonin, and serotonin transporters, may have enduring effects on serotonergic functioning of offspring later in life. Together, these findings show that there are long-term effects of both SSRIs and maternal stress on the serotonin system of the hippocampus and that the timing and duration of maternal stress (pregestational versus prenatal), as well as offspring age and sex, may mediate these effects on the developing serotonergic system. Therefore, understanding how fluctuations in serotonin and the serotonergic system impact developing neuroplasticity via early-life SSRIs, and maternal stress, is critical in integrating what we know about hippocampal plasticity in offspring.
Perinatal SSRIs and biomarkers of neuroplasticity in clinical research
Findings from clinical studies are starting to point to an effect of prenatal SSRIs on fetal and neonatal neurodevelopment by investigating biomarkers in peripheral fluids related to central nervous system development. It has been reported that prenatal SSRIs decrease S100B, an astroglial-specific Ca2+-binding protein [53, 54] in human neonates at birth [55] . S100B mediates the positive outgrowth and survival of neurons [56, 57] and stimulates glial cell proliferation [58] ; therefore, S100B levels in human biological fluids may be a useful indicator of brain maturation and the impact of prenatal drug exposure on neural development [55] . Since this reduction in S100B occurs when controlling for maternal levels of depression, which serves as a confounding variable in clinical work [5] , such outcomes imply a significant effect of perinatal SSRI exposure itself on potential markers of neurodevelopment. In addition, reelin levels are decreased in neonates prenatally exposed to SSRIs [59] . Reelin is an important glycoprotein which plays a critical role in neuronal migration and positioning during neurodevelopment, and these findings further suggest an effect of early-life changes in serotonin, via SSRIs, on the brain of developing offspring. Recent imaging data has confirmed that prenatal SSRIs do indeed alter the developing brain, at least in very preterm infants, with prenatal SSRI-exposed infants showing decreased activity in the basal ganglia and thalamus [60] . However, due to limitations in the ability of clinical P1-21 -Fluox tends to decrease BDNF exon IV mRNA levels and increase MeCP2-specific enrichment at this promoter.
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Perinatal SSRIs and plasticity in the hippocampus
With clinical work pointing to an effect of perinatal SSRIs on both S100B and reelin, key players in neural migration and plasticity, it is not surprising that there is growing interest in the long-term impact of SSRIs on hippocampal neurogenesis and plasticity. The hippocampus is one of two brain regions where there is a remarkably high rate of neurogenesis throughout the lifespan (the other region being the subventricular zone) [61, 62] . These new neurons, and their ability to form and establish new connections in the hippocampus, play an important role in learning and memory, stress regulation, and, as determined more recently, social behaviors [62] [63] [64] [65] [66] . The hippocampus consists of three main regions: cornu ammonis 1 (CA1), cornu ammonis 3 (CA3), and the dentate gyrus, the latter being a site with a high rate of continuous neurogenesis in adulthood (Fig. 1 ) [67, 68] . Understanding how neurogenesis and neuroplasticity may shift following perinatal SSRIs will further clarify the role that early-life exposures have on neurobehavioral development.
To date, findings have highlighted the long-term effects of perinatal SSRIs on hippocampal plasticity in rodent offspring, particularly after maternal stress. These studies have primarily focused on measures of brain-derived neurotrophic factor (BDNF), neurogenesis, and synaptic modifications in the hippocampus. Of particular importance are alterations of BDNF signaling, epigenetic changes in the BDNF gene, and changes in hippocampal plasticity, which have been strongly implicated in the pathophysiology and treatment of mood disorders during adulthood [69, 70] . Developmental exposure to SSRIs has resulted in long-term impact on BDNF in offspring: early developmental treatment with fluoxetine can induce longlasting behavioral impairment, via increased inhibition to stressful events and reduced behavioral despair, accompanied with upregulation of hippocampal BDNF mRNA and TrkB mRNA levels in adult male mice [41] and a decrease in global DNA methylation in the hippocampus of male rats [43] . Serotonin transporter (5-HTT) knockout rats, which have elevated levels of serotonin throughout life, display decreased BDNF levels in the hippocampus, concomitant with increased DNA methylation at BDNF promoters IV and VI [71] . An exact comparison between perinatal SSRI exposure and 5-HTT KO rat models with regard to BDNF levels and methylation status has not been carried out; however, it is likely that the apparent differences between models on BDNF effects in the hippocampus are due to the fact that 5-HTT KO animals have elevated levels of serotonin throughout life and not just during the perinatal period. While this work suggests an effect of perinatal SSRI exposure on BDNF, these three previous studies did not investigate female offspring. We have recently reported in adult female rat offspring that early-life exposure to SSRIs (fluoxetine) increases immobility in the forced swim test, decreases hippocampal BDNF exon IV mRNA levels, and increases levels of the repressive histone 3 lysine 27 tri-methylated mark at the corresponding promoter [46] . We also found a significant negative correlation between hippocampal BDNF exon IV mRNA levels and immobility in the forced swim test, with higher hippocampal BDNF mRNA expression being associated with less immobility in this test [46] . In adult male offspring, developmental fluoxetine exposure decreased BDNF IV and TrkB mRNA expression in the hippocampus and these changes were not associated with changes in the immobility measure [47] . In addition, adult male offspring showed an enduring effect of prenatal stress in decreasing hippocampal BDNF IV mRNA expression [47] , further demonstrating that these effects are sexually differentiated following SSRI exposure. Regardless, perinatal SSRI effects on epigenetic modifications and changes to BDNF signaling, a critical growth factor required for neuronal growth and development, suggest an impact on additional aspects of neurodevelopment such as neurogenesis and neuroplasticity.
Early-life exposure to SSRIs reduces cell proliferation in the hippocampus of adolescent offspring [42] . However, when combined with a model of maternal stress, early-life exposure to SSRIs prevents the effects of maternal stress on hippocampal neurogenesis (immature neurons) in adolescence and adulthood [42, 45] . These effects occur in both male and female offspring. Others have shown similar effects with postnatal SSRIs preventing the reduction in hippocampal cell proliferation and increased cell death observed in juvenile rat offspring subjected to premature maternal separation [40] . Developmental exposure to fluoxetine can also have a sexually differentiated effect on the number of immature neurons after maternal corticosterone treatment [48] , with maternal postpartum fluoxetine increasing the density of immature neurons via doublecortin expression in the hippocampus of adult male offspring but decreasing the density of immature neurons in adult female offspring. Interestingly, additional reports found no effects of perinatal fluoxetine on hippocampal neurogenesis in the dorsal hippocampus at weaning or in preadolescent offspring [37, 38] . Thus, it appears that after adolescence and puberty, the effects of perinatal SSRIs on hippocampal neurogenesis and plasticity become pronounced and sexually differentiated.
With regard to perinatal SSRI effects on spine densities and synaptic proteins, these effects appear to be primarily dependent on offspring age and sex. For example, early postnatal treatment with fluoxetine reverses the reduction in CA3 spine and synapse density observed in prenatally stressed juvenile and adolescent male mice (females were not studied) [36] . However, in rat offspring at weaning, we found no effect of early-life exposure to fluxotine on presynaptic protein densities (via synaptophysin-immunoreactivity) in the CA3 or dentate gyrus [38] . Effects on spine density appear to emerge during preadolescence, with preadolescent female, not male, rat offspring perinatally exposed to fluoxetine showing increased hippocampal presynaptic density in the dentate gyrus [37] . These effects are region-specific, with perinatal fluoxetine exposure increasing CA2 density in preadolescent females but decreasing such density in combination with pregestational maternal stress exposure. As previously mentioned, although females seem particularly sensitive to the effects of perinatal fluoxetine exposure, male offspring appear particularly sensitive to maternal stress and depression [37] . For example, preadolescent males, but not females, exposed to perinatal fluoxetine show reductions in presynaptic density and immature neurons in the dentate gyrus following pregestational maternal stress [37] . Furthermore, SSRI exposure appears to affect the developmental trajectory of synaptic protein density, with adult female, but not male, offspring exposed during lactation/suckling to SSRIs showing significantly reduced presynaptic density in the dentate gyrus [45] . This enduring effect of SSRIs on synaptic proteins extends recent work showing that perinatal fluoxetine exposure can reduce perineuronal nets in the CA1 and DG region of juvenile mice hippocampi [44] . In addition, postnatal fluoxetine treatment significantly alters gene expression related to hippocampal synaptic functioning and neurogenesis in selectively bred "Low Responder" rats predisposed for increased anxiety and behavioral abnormalities [72] . Thus, there is a likely role for perinatal fluoxetine exposure in altering hippocampal synaptic plasticity during development: effects that are likely sexually differentiated and age-dependent (Table 1) .
SSRIs and sex effects on hippocampal plasticity
As mentioned above, there is a persistent effect of sex in mediating perinatal SSRI exposure effects on hippocampal plasticity in adulthood. For example, adult female offspring, but not male offspring, exposed early in life to SSRIs have increased new cell survival, decreased BDNF mRNA expression, and reductions in hippocampal synaptophysin density in the granule cell layer [45] [46] [47] . Others have shown that maternal postnatal fluoxetine treatment increases adult male immature neuron density in the hippocampus via doublecortin expression while reducing such density in the adult female hippocampus [48] . Changes in steroid hormone levels during puberty likely contribute to sex-dependent SSRI sensitivity and structural changes in the hippocampus as a result of altered estrogen and androgen receptor expression [73] [74] [75] . Serotonin plays a key role in sexual differentiation through its role in the development of the hypothalamic-pituitary-gonadal (HPG) axis [76, 77] . The inhibition of the natural drop in serotonin in the first week of life resulting from SSRI exposure likely antagonizes the perinatal masculinization effects of testosterone during the second and/or third week postpartum and alters feminization of the brain. Previous work has shown that postnatal stimulation of serotonin synthesis, by injection of L-tryptophan, inhibits female sexual behavior and has an inhibitory effect on postnatal "organization" of female sexual behavior as well as on "activation" of female sexual behavior in adulthood [76, 77] . In addition, a defeminization of sexually dimorphic brain structures in females results from early-life stimulation of the serotonin synthesis [78] and, conversely, treatment with parachlorophenylalanine, a serotonin synthesis inhibitor, enhances masculinization and defeminization [78, 79] . Therefore, sexually differentiated effects of perinatal SSRIs on hippocampal plasticity may be a result of changes to the serotonergic system early in life, as serotonin plays a role in sexual differentiation of the brain via development of the HPG axis [76, 77] .
The role of maternal stress
As shown above, the effects of perinatal SSRIs can differ in the presence of maternal stress in some regards, the effects of maternal stress being more pronounced and enduring than the effects of SSRIs. For example, maternal stress, regardless of perinatal SSRI exposure, significantly reduces presynaptic densities in preadolescent male, but not female, offspring and decreases the number of immature neurons in the granule cell layer of dentate gyrus in preadolescent and adult male, but not female, offspring [45] . Interestingly, pregestational maternal stress effects on offspring are in agreement with a number of studies showing that perinatal maternal stressors reduce hippocampal neurogenesis and plasticity later in life, particularly in males [80, 81] . In line with this, an increasing amount of clinical research is reporting that child development outcomes are often more affected by maternal depression and associated risk factors prior to conception than by perinatal SSRI exposure [5, 21, 22 ]. Thus, a mother's level of stress and depression during the perinatal period and prior to gestation can have a long-term impact on neurobehavioral outcomes in offspring, regardless of, or in addition to, perinatal SSRI effects. More research is needed to investigate additional therapeutic approaches which treat the effects of perinatal depression in both mothers and offspring.
Summary and future directions
It is clear that perinatal SSRIs can have a long-term effect on plasticity in the hippocampus of offspring. Perinatal SSRIs can at times protect against the effect of maternal stress, have effects independent of maternal stress, and have effects on offspring that are sexually differentiated. The effects of perinatal SSRIs on hippocampal plasticity may be both direct, due to perinatal drug exposure, and indirect, with effects mediated by maternal care as well as SSRI effects on the placenta [17, [82] [83] [84] . Apart from effects on hippocampal plasticity, a growing body of literature shows that perinatal exposure to SSRIs affects a number of neuroendocrine systems and neurobehavioral outcomes which may be linked to the hippocampus. For example, developmental exposure to SSRIs alters the HPG axis [79, 85] and the hypothalamic-pituitary-adrenal axis [36, 86, 87] and has been linked to poor social behaviors and increased mood disorders in children [34] . However, there are also persistent effects of maternal stress and maternal mood on childhood outcomes, even with maternal treatment of SSRIs [5, 21, 22] .
What is abundantly clear is that untreated maternal depression is not an option for the mother or developing child. SSRIs are often the first-line treatment for maternal mood disorders and these medications are more effective if combined with psychotherapy. However, there are a number of treatments available that may also be beneficial to the mother, such as psychotherapy alone, parenting classes, exercise, and diet change [13, 88, 89] . Regardless, the goal is to effectively treat the mother as the risk of untreated maternal depression outweighs the risk of the SSRI treatment exposure. On the other hand, many pregnant women prescribed SSRIs also remain depressed and anxious and this is detrimental to the mother, child, and family. Therefore, SSRI treatment for maternal affective disorders during pregnancy should be treated on an individualized basis which takes into account depression severity, likelihood of treatment response and probability of adverse fetal effects, and individual patient values and health [90] . The data reviewed here suggest that future treatment for maternal affective disorders may also need to consider offspring sex as well as SSRI timing and dosage.
Unfortunately, to date, there has been very little research on the neurobiology of maternal mental illness, even though one in seven women suffer from perinatal depression or clinical levels of perinatal anxiety [4] . Thus, more research is needed to understand the mechanisms behind maternal mental illness in order to develop effective and safe treatments for these disorders. Only then will we be able to improve the health and well-being of the mother and child. 
